Lysophosphatidic acid is a bioactive mediator in ovarian cancer

Xianjun Fang, Michel Schummer, Muling Mao, Shuangxing Yu, Fazal Haq Tabassam, Ramona Swaby, Yutaka Hasegawa, Janos L. Tanyi, Ruthie LaPushin, Astrid Eder, Robert Jaffe, Jim Erickson, Gordon B. Mills

Research output: Contribution to journalReview articlepeer-review

228 Scopus citations

Abstract

Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that exhibits pleiotrophic biological activities, ranging from rapid morphological changes to long-term cellular effects such as induction of gene expression and stimulation of cell proliferation and survival on a wide spectrum of cell types. LPA binds and activates distinct members of the Edg/LP subfamily of G protein-coupled receptors that link to multiple G proteins including G(i), G(q) and G(12/13) to elicit cellular responses. LPA plays a critical role as a general growth, survival and pro-angiogenic factor, in the regulation of physiological and pathophysiological processes in vivo and in vitro. Our previous work indicates that abnormalities in LPA metabolism and function in ovarian cancer patients may contribute to the initiation and progression of the disease. Thus, LPA could be a potential target for cancer therapy. This review summarizes evidence that implicates LPA in the pathophysiology of human ovarian cancer and likely other types of human malignancies.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Volume1582
Issue number1-3
DOIs
StatePublished - May 23 2002
Externally publishedYes

Keywords

  • Cancer therapy
  • Cell survival
  • Edg receptor
  • Lysophosphatidic acid
  • Ovarian cancer

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Lysophosphatidic acid is a bioactive mediator in ovarian cancer'. Together they form a unique fingerprint.

Cite this